Collaborating with Confidence by Dr. Jared R. Robbins, Dr. J. Brett Mangum and Riley M. Goldsmith

Collaborating with Confidence 

Keys for improving communication between dentists and radiation oncologists


by Dr. Jared R. Robbins, Dr. J. Brett Mangum and Riley Goldsmith


Purpose
The purpose of this article is to provide dentists with tools and information to help improve collaboration and communication between dentists and radiation oncologists in the management of head and neck cancers (HNCs). This article will highlight key principles of HNCs, radiation oncology treatment paradigms, important points about the multidisciplinary management of HNC patients, and provide a framework for dentists regarding what questions they should ask radiation oncologists. By fostering collaboration, improving the basic understanding of modern radiation therapy and knowing the questions to ask, dentists can confidently mitigate the risks of radiation-related dental complications.

Case report
The following case report highlights the quintessential nature of collaboration between dentists and radiation oncologists. In particular, the following case explains why it is essential for dentists to possess a basic understanding of the field of radiation oncology and know the types of questions to ask when managing a patient being treated with radiation therapy for HNCs.

A 70-year-old male patient presented as a new patient to a dental office with a chief complaint of a loose maxillary left second premolar. The patient’s medical history was significant for human papilloma virus positive (HPV+) squamous cell carcinoma of the left tonsil. It was treated with radiation therapy (RT) 1.5 years previously. Previous dental records were requested and reviewed with the following pertinent items:
  • A pre-radiation exam showed a periapical lesion on tooth #14 at the mesial-buccal root with a “hopeless” long-term prognosis (Fig. 1).
  • The periapical radiograph of #14 and a panoramic radiograph would be sent to the radiation oncologist to determine whether the oncologist wanted the dentist to remove the tooth. No further communication was received, and the tooth was not extracted. The patient wanted to save the tooth.
  • The chart notes that radiation treatment would likely start in a week.
  • The patient presented 1.5 months later with pain and radiation-induced mucositis. Magic mouthwash, Hurricaine spray, and prescription-strength fluoridated toothpaste were recommended. The need to extract tooth #14 was mentioned in the chart, and grade II mobility, recession and furcation involvement were noted during every follow-up care visit, every four months, for one year after radiation. A referral was made to a periodontist for treatment of tooth #14.
  • One year after the completion of RT and in conjunction with the advice of the community radiation oncologist, but with no actual reference to the radiation plan, the patient had hyperbaric oxygen therapy (HBO) followed by extraction of tooth #14 and bone graft. After healing, an implant was placed.
Collaborating_Robbins
Fig.1: Pre-radiation panoramic radiograph, showing a periapical lesion on tooth #14 at the mesial-buccal root with a “hopeless” long-term prognosis.

The patient’s immediate concern was pain and mobility of #13, just anterior to the implant site, and he wanted treatment options for that tooth. A call was placed to the radiation oncologist (RO), but twice, the call was lost when transferred to the treatment personnel. A message was left, but not immediately returned. Eventually, the receptionist gave the dentist the radiation oncologist’s cell phone. Throughout the call, the dentist made a concerted effort to ask specific and informed questions about the radiation. During the discussion regarding treatment options for #13, the RO mentioned that he liked HBO, but knowing that the risks of osteoradionecrosis and the benefits of HBO were dependent on the radiation dose to the area of concern, the dentist specifically asked if the RO would mind looking up the treatment plan to help determine how much radiation dose the left maxilla had received near #13. The RO was a little resistant and reiterated that he liked HBO, but eventually relented and looked at the radiation plan. Upon review, it was discovered that the area of tooth #13 (and tooth #14, which was previously extracted after HBO) had received less than 5 Gy of radiation, which would make it very low risk of complication after extraction. Given this information, it was decided that HBO would not be necessary for the extraction and subsequent treatment of #13.

No further mention was made about the previous 6-week course of HBO therapy, which was likely not necessary or extraction, bone graft, and implant placement that had previously been done for #14. In this case, knowing what to ask, understanding the basics of radiation-induced dental complications, and being diligent and proactive spared the patient unnecessary treatment and assuaged the dentist’s fears and anxiety regarding post-radiation extractions.


Introduction to head and neck cancers
The most common risk factors for the development of HNCs are tobacco, alcohol, viral infections such as human papilloma virus (HPV), Epstein-Barr virus (EBV), and poor oral/ dental hygiene.1 Squamous cell carcinoma (SCC) accounts for the largest subgroup of HNCs, which can be further subdivided into HPV+ and HPV- SCC. This delineation is not without clinical significance as the presence of HPV+ SCC changes staging, treatment and overall prognosis.

In the late 1980s, about 17% of oropharynx cancers were HPV+. Presently, nearly 70% of oropharyngeal cancers are now HPV+. It is important to note that HPV+ SCC is associated with a favorable overall survival (OS) and generally affects younger individuals. Together, this data suggests the management of these patients must now be considered in terms of decades rather than years, and treatment protocols need to account for not only efficacy but toxicity and longevity.1,2

Patients with HPV+ tumors will likely need long-term dental solutions and effective preventative strategies to mitigate the related dental risks even years after cancer treatment. Effective collaboration between medical and dental professionals is thus imperative in anticipating and managing treatment-related sequelae for these otherwise long-living patients.

Primary tumor locations for HNCs are the oral cavity, oropharynx, larynx, nasopharynx and sinus. Lymph node involvement can be unilateral or bilateral with coverage increasing the radiation field and subsequent radiation delivered to nearby healthy tissues. The more extensive the spread, both locally and to the regional cervical neck lymph nodes, the more volume of normal tissue will receive high doses of radiation therapy, which can impact long-term xerostomia, chewing, eating, speaking and swallowing.

In terms of radiation management, the general treatment regimens are as follows: definitive treatment with organ preservation representing about seven weeks of treatment, post-surgical sterilization of the tumor bed corresponding to about six weeks of radiation, and palliative treatment in the setting of pain and functional debilitation ranging anywhere from one treatment to two and a half weeks. The anatomic location and stage guide whether radiation is indicated and whether it will fall into the neoadjuvant (before surgery), adjuvant (after surgery) or definitive (no surgery) setting.

Every patient warrants multidisciplinary discussion. However, it is important to understand the association between delayed treatment and overall survival. A systematic review of nearly 51 studies indicates that increased time from diagnosis to treatment is associated with worse overall survival for HNCs.3

Excessive delays for dental evaluation and pre-radiation dental procedures can allow the cancer to grow and spread, which can impact cancer outcomes. Therefore, efforts to improve communication and collaboration and expedite dental evaluation and treatment will not only decrease post-treatment toxicities but also improve outcomes like survival.


Introduction to radiation oncology
The following terms and definitions are to establish a common vocabulary when discussing the treatment of patients:
  • Grey is the unit of measure that is used in modern times to denote the amount of radiation that is given.
  • 3D conformal is the old technique of radiation delivery which is less conformal than modern techniques; in turn, delivering more radiation to surrounding healthy tissues. This would be considered archaic for most radiation treatment plans today with limited exceptions. This is what was typically thought of as treatment fields.
  • Intensity-modulated radiation therapy (IMRT) is a complex radiation technique that limits high doses to surrounding structures through innovative technological advances that utilize complex beam arrangements and automated modulation techniques. (Volumetric arch therapy (VMAT), rapid arc and tomotherapy are newer variations of IMRT.) This technique uses photons/X-rays to target the cancer cells. This is currently the standard of care at most radiation centers. It focuses on treatment volumes and limiting doses to normal structures.
  • Intensity-modulated proton therapy (IMPT), or proton therapy, limits exit dose past the target of interest, which spares normal tissue. This is accomplished by using proton (positively charged) rather than photon/X-ray energy sources. This is a newer and much more expensive therapy that is only available at 45 centers in the U.S. Early studies suggest it may help reduce radiation toxicity for HN patients.
  • Isodose lines refer to lines used to delineate the dose of radiation to specific locations. They are typically generated by overlaying the radiation treatment plan over a CT scan of the patient. It is viewed like a topographical map with various lines or colors reflecting the dose to that area. These help the RO ensure the tumor coverage and sparing of normal structures (Fig. 2).
  • Dose-volume histograms are graphical depictions of what volume of the tumor/target or normal structures receive a specific radiation dose. Through rigorous studies, various doses to specific volumes are associated with a specific outcome. For example, the volume of the mandible that received more than 60 Gy correlates with the risk of osteoradionecrosis, so the radiation oncologist will use metrics, such as less than 15% of the mandible should receive 60 Gy, to try to limit the risks to the patient. These are part of the medical chart and can be reviewed to evaluate the dose to various structures related to dental management and the associated risks (Fig. 2).
  • Fraction, in general, refers to the number of treatments for each radiation plan. Thirty fractions means that the patient will come 30 times to the office to receive radiation.
Collaborating_Robbins
Fig. 2: Dose volume histogram (left) depicts each target/organ-at-risk based on the volume that receives a specific dose. Isodose lines (right) delineates the dose to various anatomic structures using lines to depict the dose overlaid on a CT scan.

The differences between new and old radiation modalities can be distilled into a general theme of selected volumes receiving specific radiation doses while sparing nearby critical organs compared to fields covering areas delineated from bony landmarks on plain film X-rays.

The general principle regarding modern radiation plans is based on creating 3D volumes based on the patient’s anatomy and tumor location with CT imaging and then using multiple beams and dose modulation to cover the target and avoid critical structures (Fig. 3).

Collaborating_Robbins
Fig. 3: Fields vs volumes: Treatment plans for T2N1 tonsil squamous cell carcinoma. 2D radiation fields (left) 2D field based on plain film imaging and bony anatomy. The initial field is blocked out in yellow, with subsequent shrinking fields of orange and then red as a final boost. Minimal critical structures were spared. IMRT plan (right) shows the delineated tumor volumes covered conformally with high-dose radiation and risk-based coverage of at-risk lymph nodes with sparing of normal organs.


Questions to ask your radiation oncologist (before and after treatment)

The intent of providing background on HNCs and radiation oncology is not only to create a shared dialogue in the multidisciplinary setting but also to create a framework for anticipating and responding to the dental needs of radiation patients. Understanding the types of questions that will maximize the oral health of a patient in the pre-and post-radiation setting is important as there is no consistent protocol for the dental management of radiation patients. Indeed, while individual papers have suggested protocols, there is not a clear consensus in the literature regarding how to optimize oral care to minimize radiation sequelae.4

Therefore, it is of paramount importance to discuss individual patients on a case-by-case basis with a radiation oncologist. The following paragraphs introduce questions that may guide treatment.


Questions to consider asking before radiation treatment
Where is the tumor located?
Tumors of the oral cavity, oropharynx, nasopharynx and paranasal sinuses typically have the most dose to the mouth, mandible, teeth and salivary glands, and are at higher risks for dental-related complications. Radiation treatment of other anatomic sites may also contribute to dental complications, particularly if the volume is large and multiple lymph nodes are involved (Fig. 4).
Collaborating_Robbins
Fig. 4: All radiation plans are unique to the patient’s disease and have varying degrees of risk of toxicity to normal structures based on the treated volume. The early larynx and advanced skin cancer cases have almost no risk of dental complication as the sites of disease are far from nearby organs at risk. However, the two tonsil cases have dramatically different toxicity profiles, despite their shared primary anatomic location because of the differing tumor extent, lymph node involvement, and the treatment volume.


Are lymph nodes involved? Unilateral vs bilateral?

The extent of lymph node involvement and the necessary treatment with radiation to the unilateral or bilateral neck determines the side effects of treatment. The greater the number of involved lymph nodes and the larger the radiation treatment volume, the higher the potential toxicity.

What will be the intended treatment modality for this patient (surgery, radiation chemo, etc.)?
Each additional treatment modality increases the potential toxicity from the treatment.

What is the radiation dose to the mandible and what will be the risk of osteoradionecrosis (ORN)?
Simply asking, “What is the dose” is not sufficient to understand the risks to the mandible. The typical dose to the tumor or post-op bed will be 60–70 Gy, but the dose to the mandible varies based on proximity to the site of the tumor and coverage of surrounding lymph node regions. This is an important distinction, as areas that received 25–30 Gy have less risk for surgical complications after radiation, while areas with more than 50 Gy are at risk for ORN with the risk increasing substantially with doses between 60–70 Gy.

What is the prognosis or five-year survival rate for my patient?
Understanding a patient’s prognosis from cancer is essential for developing an appropriate dental plan. Patients with low-risk HN cancer, like low volume HPV+ tumors, will likely survive their cancer (90% five-year survival) and will need proactive long-term dental care, while for those with more aggressive tumors establishing a rigorous five year dental plan may not be as important. Particularly when the radiation plan is palliative in nature and the goal is symptom relief, rather than cure, the risks of long-term dental complications are very low because of the lower overall radiation dose and limited life expectancy. Regardless of the prognosis and radiation plan, symptomatic teeth or those at very high risk of infection need to be addressed, but the methods and the aggressiveness of the treatment should reflect how long the intervention needs to last and the risks associated with it.

When will radiation begin?
This is paramount, as the risk of extractions is typically lower before radiation. Arranging dental evaluations as soon as possible and expediting dental treatment helps ensure the best outcomes. After extraction, patients need time to heal before starting radiation, and excessive delays can result in inferior cancer outcomes.

What is the risk of post-treatment xerostomia (dose to the salivary glands)?
Salivary glands are sensitive to the effects of radiation therapy. There are four major salivary glands and multiple minor ones. The parotid glands produce the stimulated saliva flow before and during meals, while the submandibular glands supply the basal salivary flow. Both are impacted by radiation and are the major cause of xerostomia. Sparing some of the salivary glands with IMRT improves quality of life and function.


Post-treatment questions
To what area was the radiation delivered? Where did the tumor originate?
The treating radiation oncologist should be able to look at the radiation plan, identify areas of concern and relay specific doses to those areas. This can be used to assess risk and guide therapy.

What was the dose to the tumor and nearby organs at risk? Specifically, what was the dose to the mandible?
Assessing the risk of developing ORN is important, as clinical suspicion for this long-term toxicity is an important first step in treatment. The current options for treatment include nutritional support, oral saline irrigation, antibiotics, pentoxifylline and vitamin E, hyperbaric oxygen, and in some cases, surgery.


Conclusion and survey
Basic knowledge of head and neck cancer treatments and the principles of radiation oncology, coupled with knowing what questions to ask, allows dentists to confidently collaborate with radiation oncologists to improve dental-related complications and overall survival. Efforts to improve collaboration and communication improve patient care and reduce provider angst. Tools are being developed to help dentists and radiation oncologists communicate more effectively. Until then, don’t hesitate to pick up the phone and call the radiation oncology team. Use the information and questions in this article to enhance your interactions and improve patient outcomes.

To further augment collaboration between radiation oncologists and dentists, we are conducting a survey-based study that was approved by the University of Arizona Institutional Review Board and is non-commercial. The survey was developed to better understand dentists’ perspectives regarding head and neck radiation. With the results, we hope to develop better tools for communicating radiation data to dentists and improve our treatment alliance. Please complete the 5–10-minute survey by scanning the QR code below.
Collaborating_Robbins

Reference
1. Chow LQM. Head and Neck Cancer. Longo DL, ed. New England Journal of Medicine. 2020;382(1):60-72. doi:10.1056/NEJMra1715715.
2. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England Journal of Medicine. 2010;363(1):24-35. doi:10.1056/nejmoa0912217.
3. Schutte HW, Heutink F, Wellenstein DJ, van den Broek GB, van den Hoogen FJA, Marres HAM, van Herpen CML, Kaanders JHAM, Merkx TMAW, Takes RP. Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review. Otolaryngol Head Neck Surg. 2020 Apr;162(4):446-457. doi: 10.1177/0194599820906387. Epub 2020 Feb 25. PMID: 32093572.
4. Schuurhuis JM, Stokman MA, Witjes MJ, Dijkstra PU, Vissink A, Spijkervet FK. Evidence supporting pre-radiation elimination of oral foci of infection in head and neck cancer patients to prevent oral sequelae. A systematic review. Oral Oncol. 2015 Mar;51(3):212-20. doi: 10.1016/j. oraloncology.2014.11.017. Epub 2014 Dec 15. PMID: 25524386.

Author Bios
Dr. Jared Robbins Jared R. Robbins, MD is a radiation oncologist specializing in treating head and neck cancer. He works at Duke University in Durham, NC. He enjoys caring for patients, teaching students and residents, doing research, and collaborating with dentists to improve oral health in cancer patients.



Riley Goldsmith Riley Goldsmith is a fourth year medical student from the University of Arizona College of Medicine-Tucson applying to Radiation Oncology. She graduated from the University of Arizona with a B.S. in physiology and a minor in biochemistry and Spanish. She is the first author of three published manuscripts.





Dr. J. Brett Mangum J. Brett Mangum, DDS, practices dentistry in Prescott, Arizona. He earned his dental degree from the University of Michigan, completed an AEGD program, and served in the Navy. He is a fellow of the Academy of General Dentistry and has lectured on dental ethics and oral cancer alongside Robbins.


Sponsors
Townie Perks
Townie® Poll
Who or what do you turn to for most financial advice regarding your practice?
  
Sally Gross, Member Services Specialist
Phone: +1-480-445-9710
Email: sally@farranmedia.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450